Detalhe da pesquisa
1.
Phase I dose-escalation and pharmacokinetic study of ispinesib, a kinesin spindle protein inhibitor, administered on days 1 and 15 of a 28-day schedule in patients with no prior treatment for advanced breast cancer.
Anticancer Drugs
; 23(3): 335-41, 2012 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-22123335